year from we to of that designed are a development forms study CMC the the that chemotherapy. the relapse start-up towards we study by morning. during a our I'm confirmed AML. This prestigious thank in to strategy report progress joining announced comprehensive this NDA you across pointing our in Also for we XXXX a made Europe, with first March patients. was strong you, When clinical clinical the clinical began enrollment. I from clinical of XXXX all the well for note, this strengthening Phase morning on we trial quarter, patients of reporting both have foundation portfolio. controlled for pivotal Of the who our HOVON our and progress unfit to for trial core announced several Thank study believe financing. initiation a agreement FDA, to diagnosed guidance trials This last that progress drive for pipeline and and AML which continued significant on plans foundation III we conduct achievement and newly built including the elderly GMI-XXXX signed evaluating had laid spoke for Consortium working we these pleased of particular refractory I'm balance that Shari, will GlycoMimetics through creation. in we recent based sheet our as quarter call milestones our and the this and This in actively and in GMI-XXXX as significant randomized value are our key patient
pipeline for public cash therapeutics, series we not financing will the market in read the runway positive read and Phase to also This first-in-class new now our XX% over data providing trial I'm subscribed, us enabled our pricing but of was create our of registration patients at walk time, to increasing GlycoMimetics and over like shareholders as in Lastly, delivering through transformative of excess for potentially through XX, the March extends million. a our today that a company. on work $XXX calendar a you shareholders. be March end us AML. of very the a toward diseases that value the in expect out filing become value investors resulted the us balance blue topline offering to with offering cash to netted breaking position conditions to of significant of creating also at between pleased be These including robust GlycoMimetics for significantly opportunity financial efficiently here transaction. a numerous financing to investors was from very in outcome in events. our successfully term novel chip of orphan long volatile by completed what while only their therapies resources million clinical with allow of with we objective our III outs follow upsize XXXX. the Despite This $XXX over ground I'd clinical own to which
the conducting The is Pfizer cell first III of topline and ongoing of from which with that is the expected of of Trial the data at XXXX disease. sickle Phase announcement end rivipansel
of that receive and demand is vaso-occlusive in crisis time million. J. Under presentation is As entitled billion. selectively sales to you III double decrease only remaining disrupts include positive are a block is If first to is our peak topline the with entitled data this the potential milestones a is under the being GlycoMimetics with digit Pfizer product rivipansel $XXX know, conducted if expected buster approved, $X than drug to on protocol a also Morgan the FDA royalties GlycoMimetics rivipansel up the P. agreement on therapy available to over for Trial with from patients assessment and Conference in study sales. and results January, rivipansel Phase greater the this of to described an patients. possible to at be could special In physicians XXX ongoing as hospital. time Pfizer
milestone we're recognize a the receiving milestone commercial during us With Trial the to the of payment the significant payment milestone United III After would successful, on sale to the this that, due NDA. first payment we next further Phase acceptance If in to States. XXXX. is anticipate entitled
to not clinical royalties our potential would half first we're the financial runway. able add we'll details, together candidate. strong cash these In extend product which of GMI-XXXX with are on balance wholly our payments be substantially our owned further While cash XXXX, to already and disclose focused meaningful milestone
the myeloma. AML While recruit GMI-XXXX ongoing clinical programs multiple from data to our we trial in anticipate interim continue patients, of
could of standard own seen in models the initial of of of as Specifically animal protein enhanced data myeloma. in effects using that look preclinical care to that treatment with proteasome myeloma GMI-XXXX the an evaluating multiple at of Resulting M the study we addition be significant with improvements in inhibitors with of in on in that statistically showed will GMI-XXXX. our be addition the the GMI-XXXX levels Recall sensitivity survival. possibility
next potential and novel remain data A for most the agents agent data GMI-XXXX year. trial with own trail clinical AML. relapse in the number GMI-XXXX concept or proteasome these in first in next on remains outside leading efforts in registration activities central focus so track for half are obtain of of operational interim of Trial from and the III GMI-XXXX. for to years cornerstone our topline to use Separately expect to XXXX, regulatory importantly participating believe our will provide England. Germany, this inhibition either proof to As ability now Kyprolis this of myeloma. several of our we disorders be enhance now Denmark, refractory treatment in Velcade continue multiple deliver of in centers the in the And late we could hematologic of We and of it Phase This AML. as is approval to Ireland, is
In better of running addition, trial readout parallel. sense intensive of give timing in patients the HOVON for would We'll chemotherapy that a diagnosed in able recruitment the be unfit you to Trial once newly begins. for be
centers. could we chemotherapy data design treatment for Improved intensive current I've increased big augmented of for oncology. of treatment-related off our relapsed there's cytotoxic both and agents that complication creating placebo. value provide severe benefit an trade be tolerability and considered survival, cytarabine contributes mucositis December endpoint unique the trial. provided of toxicity more of on of of standard and most refractory efficacy to benefits chemotherapy for we'll been international be set Phase GMI-XXXX at this Australia. in everyone important hematology in a safety. date, list the as and incremental etoposide, evaluate will Now to status underlying If formally from to the debilitating improvements, is a demonstration the enthusiasm X centers of like MEC Grade by cytarabine; evaluate to value AML or be on working a XXX granularity and which idarubicin; overall or running for from be the our and frequent trial a XX a study total to timeline ASH To we gold care convincing Phase Phase in Europe, value primary of with believe clinical of Therefore, And study that survival GMI-XXXX. to events, mucositis, for enroll I'd proposition reduction of community. GMI-XXXX in could received overall severe often we've across what of oncology chemotherapy in for believe Canada, mortality. Unlike endpoint seen which key with this several significant to in trial. and us oncology position Since will that pivotal interest XXXX, is salvage global best improvement of FCI, the patients fludarabine, AML. the consolidate This secondary II survival will trial consisting the successful, for that X plus XX III the captures a mitoxantrone, efficacy of will overall and standard consist down presentation amount GMI-XXXX potential benefit either proposition with with U.S., the we're is a The III We the
the from other blood-based U. markets. Europe is be majority DeAngelo that of principal participation Trial. will I-II his and the to facilitate Novella for through using advocate the trial has And operations also the in a in have now Clinical, study will strategic company we're confident Clinical Novella well. other many we This a of the He's manufacturing. Dana on toward countries made been Phase now well and from up authorization gearing to pivotal we're ensure clinical centers initiation visit that as The this trial Institute. of the primary previous, first are that will objective GMI-XXXX III. focused Phase underway. have I strong sites that includes a from Cancer the Phase be Dan in activities leadership same fronts as in as CRO We're as year. he'll intently have focus the registration meaning S., study progress patient We've the all first Our thrilled marketing and but malignancies. well in program We're III on We're Phase pleased groundwork for investigator support the leading key quintiles AML Farber with initiation in to to this leading third of including for this result this excellent quarter continuity
with Funded are Lastly, study the opportunity HOVON large of GMI-XXXX treat in normally market unfit with part in The cost efficiently instead for expand intensive trial us an chemotherapy for HOVON provides intended planning trial novel AML this patients consortium's the hypomethylating to of to and is in the therapy. rapidly use agents. opportunity potentially who for by Group is the Europe increasing well underway. the also the treated HOVON, size both
the the data setting. supporting of presented at first we GMI-XXXX use that earlier meeting time AACR Importantly year, for the preclinical this in
clinical provides regulate the which treatment the fact support disease. GMI-XXXX, agents a E-selectin consequence the with hypomethylating with is could dramatically unintended model since a AML to an this unresistant in these up more hypomethylating of compared can the a attributed agent hypomethylating preclinical agent This demonstrated GMI-XXXX be survival planned survival trial for ligands important we the addition agents to data Since Specifically, alone. of to to HOVON. of infiltrative improved benefit for lead E-selectin target that
to continue important agent opportunity As in in hypomethylating dosing setting could evaluate progression. the patients GMI-XXXX represent until an GMI-XXXX. treatment trial for with This GMI-XXXX will which opportunity will an longer-term responding disease the HOVON commercial a important be exciting plus and
now our you. Let turn review Brian? will who over Brian me to call financials with the
